AUSAF (Australis Capital) 3-Year EBITDA Growth Rate: 0.00% (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Australis Capital 3-Year EBITDA Growth Rate?

Australis Capital AUSAF -90.00% 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2021.

Australis Capital's EBITDA per Share for the three months ended in Dec. 2021 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Australis Capital  (OTCPK:AUSAF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Australis Capital 3-Year EBITDA Growth Rate Related Terms

AUSAF vs ZTS, CTLT, VTRS: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Australis Capital's 3-Year EBITDA Growth Rate falls into.


Australis Capital 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Australis Capital (AUSAF) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2021. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Australis Capital and its competitors.
Is Australis Capital's 3-Year EBITDA Growth Rate too high?
Australis Capital's current 3-Year EBITDA Growth Rate is 0.00%.
How does Australis Capital's 3-Year EBITDA Growth Rate compare to ZTS and CTLT?
Australis Capital's 3-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Australis Capital and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Australis Capital (AUSAF), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.